Blockade of the immune checkpoint molecule programmed‐cell‐death‐protein‐1 (PD‐1)
yielded promising results in several cancers. To understand the therapeutic potential in …

Blockade of immune cell co-inhibitory receptor PD-1 using monoclonal antibodies enables
anti-tumor immune responses in various solid tumors and lymphoid malignancies. Our …

Purpose: Glioblastoma (GBM) is the most common primary malignant tumor in the central
nervous system. Our recent preclinical work has suggested that PD-1/PD-L1 plays an …

Glioma is the most common primary brain tumor. Programmed death 1 (PD-1) is a surface
receptor expressed on activated and exhausted T cells, which mediate T cell inhibition upon …

Background Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its
ligand (PD-L1) showed activity in several cancer types. Methods We performed …

The advent of checkpoint immunotherapy, particularly with programmed death‐1 (PD‐1) and
programmed death‐ligand 1 (PD‐L1) inhibitors, has provided ground‐breaking results in …

The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies
with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can …

Purpose: Anti-programmed cell death protein 1 (PD-1) therapy has demonstrated
inconsistent therapeutic results in patients with glioblastoma (GBM) including those with …

Gliomas are the most common type of primary brain tumor in adults. High-grade neoplasms
are associated with poor prognoses, whereas low-grade neoplasms are associated with 5 …

T cell exhaustion occurs during chronic infection and cancers. Programmed cell death
protein-1 (PD-1) is a major inhibitory checkpoint receptor involved in T cell exhaustion …